• Wir über uns
• Zentren
• Kliniken
• Institute
• Zentrale Dienste
• Medizinische Fakultät
• Pflegemanagement

| Home > Zentren > Zentrum für Operative Medizin > Klinik und Poliklinik für Gynäkologie > Publikationen

Publikationen der Klinik für Gynäkologie

Publikationen 2011

• Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer .
  Wölber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jänicke F, Mahner S, Milde-Langosch K, Müller V, Ihnen M (2011)
  BMC Cancer, in press
  
  
• EGFR gene copy number increase in vulva carcinomas is linked with poor clinical outcome.
  Wölber L, Hess S, Bohlken H, Tennstedt P, Eulenburg C, Simon R, Gieseking F, Jänicke F, Mahner M, Choschzick M (2011)
  Journal of Clinical Pathology, in press
  
  
• Serum Carbonic Anhydrase IX (CAIX) and its prognostic relevance in vulvar cancer
  Kock L, Mahner S, Choschzick M, Eulenburg C, Milde-Langosch K, Schwarz J, Jänicke F, Müller V, Wölber L (L.K. and S.M. contributed equally to this work) 2011:
  Int J Gynecol Cancer, in press 
  
  
• HRT beim metabolischen Syndrom.
  Bühling KJ. (2011)
  Gynäkol Geburtsmed Gynäkol Endokrinol, in press.
  
  
• Schilddrüse und Schwangerschaft.
  Bühling KJ. (2011)
  Seminar in Gynäkologischer Endokrinologie, in press.
  
  
• Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly elevated ALCAM expression in metastases of the skin.
  Ihnen M, Kilic E, Köhler N, Löning T, Witzel I, Hagel C, Höller S, Kersten JF, Müller V, Jänicke F, Milde-Langosch K. (2011)
  J Clin Pathol, in press
  
  
• Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer - a single-center experience 
  Witzel I, Kantelhardt E, Milde-Langosch K, Ihnen M, Zeitz J, Harbeck  N, Jänicke F, Müller V (2011) Onkologie, in press
  
  
• PREPARE trial.  A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel and darbepoetin alfa in primary breast cancer - results at the time of surgery.
  Untch M, Fasching P, Koch F v, Conrad U, Fett W, Kurzeder C, Lück H -J, Stickeler E, Urbaczyk H, Liedtke B Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, Minckwitz G v  on behalf of the AGO PREPARE investigators (2011).
  Ann Oncol, in press
  
  
• PREPARE trial  A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel and darbepoetin alfa in primary breast cancer - long term results.
  Untch M, vMinckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück H -J, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Loibl S, Fasching P  on behalf of the AGO PREPARE investigators (2011)   
  Ann Oncol, in press
  
  
• Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy  Fourty one months median follow up data of the multicenter TECHNO trial
  Untch M, Fasching P, Konecny G, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta K, von Minckwitz G, Loibl S (2011)
  J Clin Oncol,  in press
  
  
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
  von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, Fasching P A, Eiermann W, Blohmer JU, Costa S D, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Juni P (2011)
  Breast Cancer Res Treat, Vol  125: 145-56, 2011
  
  
• Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Karn T, Ruckhaberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gatje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A (2011)
  Breast Cancer Res Treat, in press
  
  
• Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
  Roth C, Pantel K, Müller V, Rack B, Janni W, Kasimir-Bauer S, Schwarzenbach H (2011)
  BMC Cancer, Vol  11: 4, 2011
  

Publikationen 2010

• Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome
  Choschzick, M, Lassen, M  P, Lebeau, A, Marx, A H, Terracciano, L, Heilenkötter, U, Jaenicke, F, Bokemeyer, C, Izbicki, J, Sauter, G, Simon, R  (2010):
  Modern Pathology 23(4):603-10
   
• Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
  Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G (2010):
  J Clin Oncol   Nov 29  [Epub ahead of print]
  
  
• Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
  Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010)
  Expert Rev Anticancer Ther  10(1):81-8  
  
  
• Comparison of pegfilgrastim on day 2 vs  day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
  Loibl S, Müller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups Support Care Cancer  2010  Oct 16  (Epub ahead of print)
  
  
• Biological role of Activated Leukocyte Cell Adhesion Molecule (ALCAM) overexpression in breast cancer cell lines and clinical tumour tissue   
  Hein, S, Müller, V, Köhler, N, Wikman, H, Krenkel, S, Streichert, T, Schweizer, M, Riethdorf, S, Assmann, V, Ihnen, M, Beck, K, Issa, R, Jänicke, F, Pantel, K, Milde-Langosch, K  (2010)
  Breast Cancer Res Treatm, in press
  
  
• A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
  Sehouli, J, Camara, O, Mahner, S, Bauknecht, T, Lichtenegger, W, Runnebaum, I, Look, K, Jaenicke, F, Oskay-Oezcelik,G  (2010):
  Cancer Chemother Pharmacol 66(5):861-8
  
  
• Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
  Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H (2010)
  Breast Cancer Res, Vol. 12: R90
  
  
• Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
  Dose-Schwarz, J, Tiling, R, Avril-Sassen, S, Mahner, S, Lebeau, A, Weber, C, Schwaiger, M,  Jänicke, F, Untch, M, Avril, N  (2010):
  Br J Cancer 102(1): 35-41
  
  
• Gene amplification in ductal carcinoma in situ of the breast
  Burkhardt, L, Grob, T J, Hermann, I, Burandt, E, Choschzick, M, Jänicke, F, Müller, V, Bokemeyer, C, Simon, R, Sauter, G, Wilczak, W, Lebeau, A  (2010):
  Breast Cancer Res Treatm 123(3):757-65
  
  
• Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/MEDM) in primary breast carcinoma and distant breast cancer metastasis 
  Ihnen, M, Köhler, N, Kersten, J F, Milde-Langosch, K, Beck, K, Höller,S, Müller, V, Witzel, I, Jänicke, F, Kilic, E  (2010)
  Dis Markers 28: 71-78
  
  
• Combination of Osteopontin and Activated Leukocyte Cell Adhesion Molecule as potent prognostic discriminators in HER2 and ER negative breast cancer 
  Ihnen, M, Wirtz, R M, Kalogeras, K T, Milde-Langosch, K, Schmidt, M, Witzel, I, Eleftheraki, A G, Papadimitriou, C, Jänicke, F, Briassoulis, E, Pectasides, D, Rody, A, Fountzilas, G, Müller, V  (2010)
  Brit J Cancer 103: 1048-56
  
  
• TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients 
  Mahner, S, Woelber, L, Eulenburg, C, Schwarz, J, Carney, W, Jänicke, F, Milde-Langosch, K, Müller, V  (2010)
  BMC Cancer 10: 139
  
  
• The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells   
  Schröder, C, Schumacher, U, Müller, V, Wirtz, R M, Streichert, T, Richter, U, Wicklein, D, Milde-Langosch, K  (2010) 
  Eur J Cancer 46: 1650-1660
  
  
• Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome  
  Witzel, I D, Milde-Langosch, K, Wirtz, R M, Roth, C, Ihnen, M, Mahner, S, Zu Eulenburg, C, Jänicke, F, Müller, V  (2010) 
   J Cancer Res Clin Oncol  136(11):1709-18
  
  
• Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer  
  Konecny, G E, Pauletti, G, Untch, M, Wang, H J, Möbus, V, Kuhn, W, Thomssen, C, Harbeck, N, Wang, L, Apple, S, Jänicke, F, Slamon, D J  (2010) 
  Breast Cancer Res Treat  20(2):481-9
  
  
• Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group  
  Eiermann, W, Graf, E, Ataseven, B, Conrad, B, Hilfrich, J, Massinger-Biebl, H, Vescia, S, Loibl, S, von Minckwitz, G, Schumacher, M, Kaufmann, M, German Adjuvant Breast Cancer Group  (2010) 
  Eur J Cancer  46(1):84-94
  
  
• Clinical management of borderline ovarian tumors  
  Trillsch, F, Mahner, S, Ruetzel, J, Harter, P, Ewald-Riegler, N, Jaenicke, F, du Bois, A  (2010) 
  Expert Rev Anticancer Ther  10(7):1115-24
  
  
• Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer  
  Woelber, L, Jung, S, Eulenburg, C, Mueller, V, Schwarz, J, Jaenicke, F, Mahner, S  (2010) 
  Eur J Surg Oncol  36(6):583-8   
  
  
• Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases  
  Choschzick, M, Woelber, L, Hess, S, zu Eulenburg, C, Schwarz, J, Simon, R, Mahner, S, Jaenicke, F, Müller, V  (2010) 
  Virchows Arch  456(5):483-90  
  
  
• Serum carbonic anhydrase IX during first-line therapy of ovarian cancer  
  Woelber, L, Mueller, V, Eulenburg, C, Schwarz, J, Carney, W, Jaenicke, F, Milde-Langosch, K, Mahner, S  (2010) 
  Gynecol Oncol  117(2):183-8 
  
  
• Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer
  Choschzick, M, Lebeau, A, Marx, A H, Tharun, L, Terracciano, L, Heilenkötter, U, Jaenicke, F, Bokemeyer, C, Simon, R, Sauter, G, Schwarz, J  (2010) 
  Hum Pathol  41(3):358-65 
  
  
• HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
  Fehm, T, Müller, V, Aktas, B, Janni, W, Schneeweiss, A, Stickeler, E, Lattrich, C, Löhberg, C R, Solomayer, E, Rack, B, Riethdorf, S, Klein, C, Schindlbeck, C, Brocker, K, Kasimir-Bauer, S, Wallwiener, D, Pantel, K  (2010) 
  Breast Cancer Res Treat  Sep 22  [Epub ahead of print]
  
  
• Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer  
  Müller, V, Thomssen, C, Schmidt, M, Glados, M, Jackisch, C, Heilmann, V, Hinke, A, Lehnert, A, Borowicz, H, Möbus, V  (2010) 
  BMC Cancer  16;10:430
  
  
• Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial  
  Witzel, I, Loibl, S, von Minckwitz, G, Mundhenke, C, Huober, J, Hanusch, C, Henschen, S, Hauschild, M, Lantzsch, T, Tesch, H, Latos, K, Just, M, Hilfrich, J, Barinoff, J, Eulenburg, C, Roller, M, Untch, M, Müller, V  (2010) 
  Breast Cancer Res Treat  123(2):437-45 
  
  
• Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies
  Lebeau, A, Turzynski, A, Braun, S, Behrhof, W, Fleige, B, Schmitt, W D, Grob, T J, Burkhardt, L, Hölzel, D, Jackisch, C, Thomssen, C, Müller, V, Untch, M  (2010) 
  J Clin Oncol  28(20):3264-70
  
  
• Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial  
  Riethdorf, S, Müller, V, Zhang, L, Rau, T, Loibl, S, Komor, M, Roller, M, Huober, J, Fehm, T, Schrader, I, Hilfrich, J, Holms, F, Tesch, H, Eidtmann, H, Untch, M, von Minckwitz, G, Pantel, K  (2010) 
  Clin Cancer Res  16(9):2634-45 
  
  
• Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies  
  Müller, V, Alix-Panabières, C, Pantel, K  (2010)  
  Eur J Cancer  46(7):1189-97 
  
  
• First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial  
  Untch, M, Muscholl, M, Tjulandin, S, Jonat, W, Meerpohl, H G, Lichinitser, M, Manikhas, A G, Coumbos, A, Kreienberg, R, du Bois, A, Harbeck, N, Jackisch, C, Müller, V, Pauschinger, M, Thomssen, C, Lehle, M, Catalani, O, Lück, H J  (2010) 
  J Clin Oncol  28(9):1473-80 
  
  
• Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data  
  Ruckhäberle, E, Karn, T, Engels, K, Turley, H, Hanker, L, Müller, V, Schmidt, M, Ahr, A, Gaetje, R, Holtrich, U, Kaufmann, M, Rody, A  (2010) 
  Eur J Cancer  46(3):549-57 
  
  
• Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study  
  Sehouli, J, Pietzner, K, Harter, P, Münstedt, K, Mahner, S, Hasenburg, A, Camara, O, Wimberger, P, Boehmer, D, Buehling, K J, Richter, R, El Khalfaoui, K, Oskay-Ozcelik, G   (2010)
  Ann Oncol  May 3  [Epub ahead of print)
  
  
• Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer - a single-center experience   
  Witzel, I, Kantelhardt, E, Milde-Langosch, K, Ihnen, M, Zeitz, J, Harbeck,  N, Jänicke, F, Müller, V  (2010)
  Onkologie,  in press
  
  
• Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies  Lebeau, A, Turzynski, A, Braun, S, Behrhof, W, Fleige, B, Schmitt, W D, Grob, T J, Burkhardt, L, Holzel, D, Jackisch, C, Thomssen, C, Müller, V, Untch, M  (2010)  
  J Clin Oncol  28: 3264-3270
  
  
• Prognostische und prädiktive Faktoren (unter Berücksichtigung von Genexpressionsanalysen)  Mammakarzinom Interdisziplinär   
  Jänicke, F, Müller, V, Harbeck, N   (2010) 
  Springer Academic Press, 98-109, (Book chapter)
  
  
• Adjuvante Chemo- und Antikörpertherapie des Mammakarzinoms  CME Praktische Fortbildung Gynäkologie
  Müller, V, Stickeler, E  (2010) 
  Geburtshilfe und Gynäkologische Endokrinologie  6: 68-79 
  
  
• ASCO 2010 - Highlights aus der Gynäkoonkologie   
  Fehm, T, Müller, V, Hartkopf, M, Schmidt, M, Becker, S  (2010)  
  Frauenarzt  51: 730-735
  
  
• News from the San Antonio Breast Cancer Symposium 2009   
  Untch, M, Bauerfeind, I, Jackisch, C, Kühn, T, Müller, V  (2010)  
  Breast Care 5: 38-43
  
  
• New Developments in Breast Cancer Therapy Presented at ASCO 2010  
  Müller, V, Dubsky, P, Fehm, T, Fitzal, F, Houber, J, Schmidt, M, Steger, G  (2010) 
  Breast Care 5: in press
  
  
• Advantages and Challenges of Oestrogen-Free Hormonal Contraception  
  Ahrendt HJ, Bühling KJ  (2010)
  Curr Med Res Opin  26:1947-55
  
  
• Role of Secondary Cytoreductive Surgery in Ovarian Cancer Relapse: Who Will Benefit? A Systematic Analysis of 240 Consecutive Patients 
  Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010)
  J Surg Oncol  102:656-62  
  
  
• Longitudinal analysis of changes in energy intake and macronutrient composition during pregnancy and 6 weeks post-partum 
  Talai Rad N, Wolf C, Wascher C, Henrich W, Siegmund T, Ritterath C, Heinze T, Siebert G, Bühling KJ 
  Arch Gynecol Obstet in press 
  
  
• Väter im Kreißsaal  Ergebnisse einer Umfrage
  Awad O, Bühling KJ 
  Geburtsh Frauenheilk in press
  
  
• Schilddrüse und Schwangerschaft 
  Bühling KJ (2010) 
  Gynakol Geburtsmed Gynäkol Endokrinol  6:44-56
  
  
• Estrogen free contraception: Progestin-only-systems 
  Ahrendt HJ, Bühling KJ (2010) 
  J  Reproduktionsmed  Endokrinol  7: 97-105
  

• Adjuvante Chemotherapie und Antikörpertherapie. Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome
  Müller V., Stickeler E.
  Zuckerschwerdt Verlag, Seite 23-40 (2009)
  
  
• Prognostic factors for complete debulking in first- and second-line ovarian cancer.
  Harter, P., Hilpert, F., Mahner, S., Kommoss, S., Heitz, F., Pfisterer, J., du Bois, A.
  Int J Gynecol Cancer. Suppl 2:S14-7 (2009)
  
  
• Clinical Relevance of Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients.
  Müller V., Janni W., Gebauer G., Solomayer E., Janni W., Pantel K.
  Breast Care, Vol. 4: 333-338 (2009)
  
  
• HER2 as marker for the detection of circulating tumor cells.
  Müller V., Pantel K.
  Breast Cancer Res Treat, Vol. 117: 535-7 (2009)
  
  
• Expression and prognostic value of L1-CAM in breast cancer.
  Schroder C., Schumacher U., Fogel M., Feuerhake F., Müller V., Wirtz R.M., Altevogt P., Krenkel S., Janicke F., Milde-Langosch K.
  Oncol Rep, Vol. 22: 1109-17 (2009)
  
  
• Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens.
  Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A, Lisboa B, Jaenicke F, Schmitt M, Vetter M.
  J Natl Cancer Inst. 2009 101 (14): 1028-1029 (2009)
  
  
• HER-2/neu analysis in breast cancer bone metastases.
  Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jaenicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G.
  J Clin Pathol. 62(6):542-6 (2009)
  
  
• Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer.
  Woelber L, Mahner S, Voelker K, Eulenburg CZ, Gieseking F, Choschzick M, Jaenicke F, Schwarz J.
  Anticancer Res. 29(2):545-52 (2009)
  
  
• Expression and prognostic value of Activating Transcription Factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
  Knippen S, Löning T, Müller V, Schröder C, Jänicke F, Milde-Langosch K. 
  Anticancer Res 29, 183-90 (2009)
  
  
• Expression of Jun and Fos proteins in ovarian tumors of different invasive potential and ovarian cancer cell lines.
  Hein S, Mahner S, Tirok C, Löning T, Jänicke F, Milde-Langosch K. 
  Oncology Rep 22, 177-83 (2009)
  
  
• Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
  Rody A, Karn T, Ruckhaberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M.
  Breast Cancer Res Treat 113, 457-66 (2009)
  
  
• Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential FDG-PET Imaging.
  Dose-Schwarz J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N.
  J Clin Oncol. 27(4):535-41 (2009)
  
  
• Intensive dose dense compared with conventionally scheduled preoperative chemotherapy for high risk primary breast cancer.
  Untch M, Möbus V, Kuhn W, Muck, BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweis A, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny G. 
  J Clin Oncol. 27(18):2938-45 (2009)
  
  
• Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
  Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology.
  Cancer Chemother Pharmacol. 64(3):585-91 (2009)
  
  
• Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
  Barthell E, Woelber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings HL, Railkar R, Gause C, Barr E.
  Arch Gynecol Obstet. 279(6): 803-7 (2009)
  
  
• German Expert Opinion on the St. Gallen Votes on March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)
  Beckmann MW, Blohmer J-W, Costa S-D, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jaenicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C. Wallwiener, D. Zurich Konsensus
  Breast Care 4: 109-116 (2009)
  
  
• Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
  Mahner S, Woelber L, Jung S, Eulenburg zu C, Ihnen M, Schwarz, Sehouli, J, Jaenicke F.
  Anticancer Res 29: 2817-2822 (2009)
  
  
• Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).
  Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Höss C, Leutner C, Braun M, Möbus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W.
  Oncol Rep. 22(3):605-13 (2009)
  
  
• Role of cytoreductive surgery in recurrent ovarian cancer.
  Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. 
  Expert Rev Anticancer Ther. 9(7):917-22 (2009)
  
  
• Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers - Results of a large scale microarray analysis.
  Rody A., Karn T., Ruckhaberle E., Hanker L., Metzler D., Müller V., Solbach C., Ahr A., Gatje R., Holtrich U., Kaufmann M.
  Eur J Cancer, 5: 405 - 413, 2009
  
  
• Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18 F]fluorodeoxyglucose
  Schwarz-Dose, J., Untch, M., Tiling, R., Sassen, S., Mahner, S., Kahlert, S., Harbeck, N., Lebeau, A., Brenner, W., Schwaiger, M., Jaenicke, F., Avril, N.
  J Clin Oncol 27: 535-541, 2009.
  
  
• Zurich Konsensus: German Expert Opinion on the St. Gallen Votes on March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)
  Beckmann, M.W., Blohmer, J.-W., Costa, S.-D., Diedrich, K., Diel, I., Eiermann, W., Friese, K., Gerber, B., Harbeck, N., Hilfrich, J., Janni, W., Jaenicke, F., Jonat, W., Kaufmann, M., Kiechle, M., Koehler, U., Kreienberg, R., v. Minckwitz, G., Moebus, V., Nitz, U., Schneeweiss, A., Thomssen, C., Wallwiener, D.
  Breast Care 2009: 4: 109-116, 2009.
  

Publikationen 2008

• Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.
  Milde-Langosch K,  Janke S, Wagner I, Schröder C, Streichert T, Bamberger A-M, Jänicke F, Löning T.
  Breast Cancer Res Treatm  107, 337-47 (2008).
  
  
• Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
  Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J.
  Ann Oncol. 19, 1249-54 (2008).
  
  
• Trastuzumab (Herceptin®) Therapy During Pregnancy associated with Poor Fetal Outcome.
  Witzel, I., Müller, V., Jänicke, F., Harps, E., and deWit, M.
  Ann Oncol, 19, 191-192, 2008.
  
  
• The similarities of aromatase inhibitors outweigh the differences.
  Jänicke, F. 
  Anti Cancer Drugs 19: Suppl 2, S7-S9 (2008).
  
  
• Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
  Ihnen, M., Müller, V., Wirtz, R.M., Schröder, C., Krenkel, S., Witzel, I., Lisboa, B.W., Jänicke, F., Milde-Langosch, K.
  Breast Cancer Res Treat 112, 419-27 (2008).
  
  
• Multicenter study using paraffin-embedded tumor tissue validates PITX2 DNA methylation for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
  Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Kluth A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R, on behalf of the EpiBreast Group. J Clin Oncol 26, 5036-42 (2008).
  
  
• Detection of metastases in breast cancer patients.
  Dose-Schwarz J, Mahner S, Schirrmacher S, Jenicke L, Müller V, Habermann CR, Brenner W
  Nuklearmed. 473, 97-103 (2008).
  
  
• Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study.
  Hillemanns P, Gabrielle Breugelmans J, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU.
  BMC Infectios Diseases  8:76 (2008).
  
  
• Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
  Fehm T, Müller V, Alix-Panabieres, Pantel K.
  Breast Can Res 10, Suppl. 1: S1 (2008).
  
  
• A comparative study of tissue inhibitor of metalloproteinase-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
  Schrohl AS, Müller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N.
  Tumour Biol 29: 181-7 (2008).
  
  
• Chemoendocrine treatment is standard in hormone receptor positive patients.
  Müller V.
  Breast Care 3: 229-230 (2008).
  
  
• Detection of minimal residual disease in predicting outcome.
  Müller V, Panabieres C, Pantel K.
  Prognostic and predictive factors in breast cancer, Informa Healthcare, 88-96 (book-chapter), 2008.
  
  
• Tumor cell dormancy: implications for the biology and treatment of breast cancer.
  Fehm T, Müller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S.
  Apmis 116: 742-53 (2008).
  
  
• C-Fos expression is a Molecular Predictor of Progression and Survival in Epithelian Ovarian Carcinoma.
  Mahner S, Baasch C, Schwarz J, Hein S, Woelber L, Jaenicke F, Milde-Langosch K.
  Br J Cancer 99: 1269-75 (2008).
  
  
• The Efficacy of Clobetasol 0.05% for Treatment of Vulvar Lichen Sclerosus.
  Schwarz J, Schwegler J, Augustin M, Ihnen M, Mahner S, Woelber L.
  Geburtsh Frauenheilk 68: 615-619 (2008).
  
  
• Mammakarzinom.
  Avril N, Bienert M, Dose-Schwarz J.
  Nuklearmedizinische Onkologie. Hrsg: Krause-Buck-Schwaiger; Ecomed Medizin Verlag, 241-257 (2008).
  
  
• PET & PET/CT: Ovarialkarzinom.
  Bienert M, Dose-Schwarz J, Avril N.
  Nuklearmedizinische Onkologie. Hrsg: Krause-Buck-Schwaiger; Ecomed Medizin Verlag, 257-267 (2008)
  
  
• Evidenzbasierte Therapie der Nausea und (Hyper)Emesis gravidarum.
  Bühling KJ, David M.
  CME Prakt Fortb Gynakol Geburtsmed Gynäkol Endokrinol 2008.
  
  
• Longitudinal changes of the Continuous Glucose Monitoring Profile in pregnant patients.
  Siegmund T, Ritterath C, Wascher C, Talai Rad N, Siebert G, Henrich W, Bühling KJ.
  Eur J Obstet Gynecol R B 139:46-52 (2008).
  
  
• Fettstoffwechselstörungen in der Schwangerschaft - eine wenig beachtete Komplikation.
  Bühling KJ.
  Dtsch med Wochenschr 133: 2177 (2008).
  
  
• Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
  Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D.
  Brit J Cancer 99: 930-38 (2008).
  
  
• Clinical significance of p53 alterations in surgically treated prostate cancers.
  Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A.
  Mod Pathol 21(11): 1371-8 (2008).
  
  
• Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.
  Briese J, Schulte HM, Sajin M, Bamberger C, Redlin K, Milde-Langosch K, Löning T, Bamberger AM.
  Virchows Arch 453(1): 89-96 (2008).
  
  

• Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
  Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terraciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R.
  Nature Genetics 39: 655-660, 2007
  
  
• Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
  Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A.
  Int J Cancer. 121:2794-800, 2007.
  
  
• Continuing with letrozole offers greater benefits.
  Jänicke, F.
  J Cancer Res Clin Oncol 133: 445-453, 2007
  
  
• Current treatment options in uterine stromal sarcoma: report of a case and review of the literature.
  Ihnen, M., Mahner, S., Jänicke, F., Schwarz, J.
  Int J Gynecol Cancer 17: 957-963, 2007
  
  
• Ulex europaeus agglutinin-I binding as a potential prognostic marker in ovarian cancer.
  Blonski K, Milde-Langosch K, Bamberger A-M, Osterholz T, Utler C, Berger J, Löning T, Schumacher U.
  Anticancer Res 27: 2785-90, 2007
  
  
• Invasionsfaktoren uPA/PAI-1 im Tumorgewebe bei Patientinnen mit primärem Mammakarzinom: Von Forschungsergebnissen zur klinischen Anwendung am Beispiel der NNBC 3-Europe-Studie
  Vetter M, Kantelhardt EJ, Annecke K, Dittmer J, Paepke D, Prechtl A, Schmitt M, Jänicke F, Minckwitz G, Kiechle-Barat M, Thomssen C, Harbeck N.
  Geburtsh Frauenheilk 67: 1144-1152, 2007
  
  
• Good agreement between physician and self-reported hormone therapy data in a case-control study.
  Kropp S, Terboven T, Hedicke J, Mutschelknauss E, Slanger T, Braendle W, Berger J, Chang-Claude J, Flesch-Janys D.
  J Clin Epidemiol 60: 1280-7, 2007
  
  
• Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy.
  Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J.
  Ann Epidemiol 17: 993-8, 2007
  
  
• Recommendations for hormonal contraception. 36th Professional Meeting of the "Zurich Discussion Group", April 2006.
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Gynakol Geburtshilfliche Rundsch 47: 94-8, 2007
  
  
• Recommendations for estrogen and progesterone substitution in climacteric and postmenopause.
  Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Gynakol Geburtshilfliche Rundsch 47: 45-8, 2007
  
  
• Detection of disseminated tumor cells in the bone marrow and blood of breast cancer patients.
  Müller V., Pantel K.
  In: Metastasis of Breast Cancer, Springer Academic press, 116-127, 2007.
  
  
• Tumorzellnachweis im Knochenmark und Blut von Patientinnen mit Mammakarzinom: Klinisches Potenzial, Studienergebnisse und aktuelle Forschungsprojekte in Deutschland.
  Müller V., Pantel K., Riethdorf S., Schindlbeck C., Rack B., Solomayer E., Janni W., Fehm T.
  Geburtshilfe Frauenheilkunde, 67: 717-720, 2007.
  
  
• Asservierung von Biomaterialien für translationale Fragestellungen im Rahmen aktueller Brustkrebsstudien. Überblick und Empfehlungen.
  vMinckwitz G., Arnold N., Denkert C., Dittmer J., Fehm T., Harbeck N., Janni W., Meinhold-Heerlein I., Müller V., Pantel K., Rody A., Schmitt M.
  Geburtshilfe Frauenheilkd, Vol. 67: 451-459, 2007.
  
  
• Der Nachweis von isolierten Tumorzellen in Knochenmark und Blut von Patientinnen mit primärem Mammakarzinom - Standardisierte Methodik und klinische Relevanz.
  Janni W., Fehm T., Rack B., Müller V., Solomayer E., Schindlbeck C., Jückstock J., Pantel K., Wallwiener D., Friese K.
  Senologie, Vol. 4: 92-98, 2007.
  
  
• DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
  Maier S., Nimmrich I., Koenig T., Eppenberger-Castori S., Bohlmann I., Paradiso A., Spyratos F., Thomssen C., Müller V., Nährig J., Schittulli F., Kates R., Lesche R., Schwope I., Kluth A., Marx A., Martens J.W., Foekens J.A., Schmitt M., Harbeck N.
  Eur J Cancer, Vol. 43: 1679-1686, 2007.
  
  
• Die klinische Bedeutung des Nachweises von isolierten Tumorzellen im Knochenmark und peripheren Blut von Patientinnen mit primärem Mammakarzinom.
  Janni W., Fehm T., Rack B., Müller V., Solomayer E., Stickeler E., Sommer H., Schindlbeck C., Jückstock J., Friese K.
  Geburtshilfe Frauenheilkd, Vol. 67: 653-660, 2007.
  
  
• Isolierte Tumorzellen in Knochenmark und Blut von Patientinnen mit Mammakarzinom - Klinische Relevanz.
  Janni W., Fehm T., Rack B., Müller V., Solomayer E., Pantel K., Sommer H., Schindlbeck C., Jückstock J., Friese K.
  Der Gynäkologe, Vol. 40: 431-439, 2007.
  
  
• Detection and characterization of putative metastatic precursor cells in cancer patients.
  Alix-Panabières, C., Vendrell, J.-P., Pellé, O., Riethdorf, S., Müller, V., Fabbro, M., Pantel, K.
  Clin Chem 53: 537-539, 2007
  
  
• Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System.
  Riethdorf S., Fritsche H., Müller V., Rau T., Schindlbeck C., Rack B., Janni W., Coith C., Beck K., Jänicke F., Jackson S., Gornet T., Cristofanilli M., Pantel K.
  Clin Cancer Res 13: 920-928, 2007
  
  
• Nachweis disseminierter Tumorzellen in Knochenmark von Patientinnen mit primärem Mammakarzinom.
  Fehm T., Müller V., Janni W., Braun S., Gebauer G., Marth C., Schindlbeck C., Wallwiener D., Borgen E., Pantel K., Solomayer E.
  Frauenarzt 48: 120-126, 2007
  
  
• Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time ofmetastatic disease by serum HER2 and HER2 status of circulating tumor cells.
  Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Müller V., Wallwiener D., Lane N., Solomayer E., Uhr J.
  Breast Can Res, Oct 26;9(5):R74 [Epub ahead of print]
  
  
• A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
  Schwarzenbach H., Müller V., Beeger C., Gottberg M., Stahmann N., Pantel K.
  Breast Can Res, 2007 Oct 3;9(5):R66 [Epub ahead ofprint]
  
  
• Current status in human breast cancer micrometastasis.
  Panabières C., Müller V., Pantel K.
  Curr Opin Oncol, Vol. 19: 558-563, 2007.
  
  
• Cox-2 is a target gene of Rho GDP dissociation inhibitor ß in breast cancer cells.
  Schunke D., Span P.N., Ronneburg H., Dittmer A., Vetter M., Holzhausen H.J., Kantelhardt E., Krenkel S., Müller V., Sweep F., Thomssen C., Dittmer J.
  Cancer Res, Vol. 67:10694-702, 2007.

• Potential clinical utility of HER-2/neu extracellular domain and soluble EGFR fragments determined in serum of metastatic breast cancer patients.
  Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V.
  Intern J Biol Markers 21: 2006
  
  
• Prognostic and predictive impact of Epidermal Growth Factor Receptor (EGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
  Müller V, Witzel I, Wilczak W, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Löning T, Jänicke F, Thomssen C.
  Anticancer Res 26: 1479-1488, 2006
  
  
• A concept for the standardized detection of disseminated tumor cells in bone marrow of patients with primary breast cancer and its clinical implementation.
  Fehm T, Braun S, Müller V, Janni W, Marth C, Pantel K, Schindlbeck C, Solomayer E.
  Cancer 107: 885-892, 2006
  
  
• The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity.
  Schrepfer S, Deuse T, Munzel T, Schafer H, Braendle W, Reichenspurner H.
  Menopause. 13(3):489-99, 2006
  
  
• Empfehlungen zur hormonalen Kontrazeption [Recommendations for hormonal contraception. 34. Workshop of the "Zürich Discussion Circle", April 2005].
  Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Gynäkol Geburtshilfliche Rundsch 46 (1-2):58-63, 2006
  
  
• Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for estrogen and progesterone replacement in climacteric and postmenopause. 33. Workshop of the "Zürich Discussion Circle", October 2004.]
  Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Gynäkol Geburtshilfliche Rundsch. 46(1-2):53-7, 2006
  
  
• Recent translational research: Circulating tumor cells in breast cancer patients.
  Müller V, Hayes D, Pantel K.
  Breast Cancer Res 8: 110, 2006
  
  
• Tumor cell dissemination and metastasis in breast cancer: Selected presentations at the 28th San Antonio Breast Cancer Symposium 2005.
  Müller V, Stickeler E.
  Breast Care 1: 113-116, 2006
  
  
• Metastasierungsmechanismen beim Mammakarzinom.
  Müller V, Pantel K, Stickeler E.
  Frauenarzt 47: 822-824, 2006
  
  
• Disseminated Tumor Cells in Breast Cancer: Detection, Characterization and Clinical Relevance.
  Woelfle U, Müller V, Pantel K.
  Future Oncology 2: 553-561, 2006
  
  
• Management of skin-sparing mastectomy: results of a survey of German hospitals.
  Dian D, Hemminger G, Janni W, Friese K, Jänicke F.
  Onkologie 29(6): 267-70 2006
  
  
• Regression von Condylomata acuminata in der Schwangerschaft nach systemischer Therapie mit Thuja.
  Ihnen M, Mahner S, Schwarz J.
  Geburtsh Frauenheilk 66: 179-182, 2006
  
  
• Operative Therapie des fortgeschrittenen Ovarialkarzinoms. Ergebnisse aus der Klinik für Gynäkologie des UKE aus den Jahren 1996-2001.
  Schwarz J, Utler C, Yekebas E, Jänicke F.
  Hamburger Ärzteblatt 1/06: 6-9, 2006
  
  
• BRCA1-IRIS regulates Cyclin D1 Expression in Breast Cancer Cells.
  Nakuci E, Mahner S, DiRenzo J, ElShamy WM.
  Exp Cell Res 312(16):3120-31, 2006
  
  
• Krankheiten der Adnexe.
  Schwarz J, Mahner S, Jänicke F.
  In: Die Gynäkologie. Kaufmann, M; Costa, SD; Scharl, A (Hrsg.). 2., überarb. Aufl., 2006
  
  
• Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
  Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Zander AR, Löning T.
  Clin Cancer Res 12: 159-68, 2006
  
  
• Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom. In: Management des Mammakarzinoms.
  Müller V., Jänicke F.
  Springer Verlag. 183-198, 2006
  
  

Publikationen 2005

• Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity.
  Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K
  Clin Cancer Res 11: 3678-3685, 2005
  
  
• Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients.
  Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Müller V, Izbicki JR, Löning T, Pantel K
  J Immunol Methods 300: 136-45, 2005
  
  
• The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system.
  Schrepfer S, Deuse T, Schafer H, Koch-Nolte F, Braendle W, Reichenspurner H.
  Transpl Immunol. 15(1):45-53, 2005
  
  
• Systemic therapy of operable carcinoma of the breast.
  Kaufmann M, Jonat W, Eiermann W, Costa S, Hilfrich J, Jänicke F, Beckmann MW, Wallwiener D, Gerber B, Rody A, Schneeweiss A, Nitz U, Köhler U, von Minckwitz G.
  Zentralbl Gynäkol. 127(4):207-12, 2005
  
  
• Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
  Dose Schwarz J, Bader M, Jänicke L, Hemminger G, Jänicke F, Avril N.
  J Nucl Med. 46(7):1144-50, 2005
  
  
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
  Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.
  N Engl J Med. 353(16):1659-7, 2005
  
  
• Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
  Von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M.
  Anticancer Drugs. 16(8):871-7, 2005
  
  
• Bone marrow micrometastases and circulating tumor cells in breast cancer patients: Where have we been, where are we now and where does the future lie?
  Müller V, Pantel K.
  Cytotherapy 7: 478-482, 2005
  
  
• St. Gallen 2005: Konsens und klinische Praxis.
  Jänicke F, Diedrich K, Jonat W, Gerber B, Lisboa B, Friedrich M, Reimer T, Maas N.
  Frauenarzt 46, 182-189, 2005
  
  
• Die Bedeutung der radikalen zytoreduktiven Chirurgie für die Überlebenszeit von Patientinnen mit fortgeschrittenem Ovarialkarzinom.
  Utler C, Osterholz T, Dose Schwarz J, Thomssen C, Jänicke F.
  Geburtsh Frauenheilk 65: 1168-1177, 2005
  
  
• Diagnostische Mammographie und Sonographie: Korrelation von diagnostischer BI-RADS-Einstufung mit dem histologischen und klinischen Endbefund [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]
  Lorenzen J, Wedel AK, Lisboa BW, Löning T, Adam G.
  Röfo. 177(11):1545-51, 2005
  
  
• Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.
  Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T.
  Br J Cancer 92: 2206-2215, 2005
  
  
• Empfehlungen zur Hormonsubstitution in Klimakterium und Postmenopause. 33. Arbeitstreffen des Zürcher Gesprächskreises Oktober 2004.
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Frauenarzt 46: 194-197, 2005
  
  
• Langzyklus.
  Braendle W.
  Gynäkologische Endokrinologie 2, 131-133 (2005)
  
  
• Benigne und maligne Tumoren unter hormonaler Kontrazeption. 34. Treffen Zürcher Gesprächskreis.
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J:
  Frauenarzt 46: 2-4, 2005
  
  
• Das Klimakterium.
  Braendle W:
  Zweite Auflage. Wissenschaftliche Verlagsgesellschaft Stuttgart (2005)
  
  

Publikationen 2004

• Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
  Schwarzenbach H, Müller V, Stahmann N, Pantel K.
  Ann N Y Acad Sci 1022: 25-32, 2004
  
  
  
• Sentinel Lymph Node Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes.
  Müller V, Kasimir-Bauer S, Pantel K.
  Molecular Oncology of Breast Cancer, Jones and Bartlett, 117-127, 2004
  
  
• Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
  Müller V, Witzel I, Lück H, Köhler G, v. Minckwitz G, Möbus V, Sattler D, Löning T, Wilczak W, Jänicke F, Pantel K, Thomssen C.
  Breast Cancer Res Treat 86: 9-18, 2004
  
  
• Laparoscopic oophoropexy for the treatment of recurrent torsion of the adnexa in pregnancy: case report and review.
  Djavadian D, Braendle W, Jänicke F.
  Fertil Steril. 82(4):933-6, 2004
  
  
• Die Zystektomie aus anderer Indikation als dem Blasenkarzinom [Cystectomy for indications other than bladder cancer].
  Hautmann S, Felix-Chun KH, Currlin E, Friedrich MG, Dose Schwarz J, Langwieler T, Conrad S, Huland H.
  Urologe A. 43(2):172-7, 2004
  
  
• Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zürich Discussion Circle, October 2003]
  Birkhauser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Gynäkol Geburtshilfliche Rundsch. 44(4):258-64, 2004
  
  
• Are all aromatase inhibitors the same? A review of the current evidence.
  Jänicke F.
  Breast 13 Suppl 1:S10-8. Review. 2004
  
  
• Operative Therapie des Ovarialkarzinoms.
  Jänicke F.
  Gynäkologe 10 : 916-928, 2004
  
  
• Recent advances in the treatment of breast cancer (Editorial).
  Smith IE, Jänicke F.
  The Breast 13: S1-S2, 2004
  
  
• How important is c-erb B2 or Her-2/neu when deciding on which therapy?
  Lisboa BW, Jänicke F.
  EJC Supplements (2) 9: 56-57, 2004
  
  
• Anthracycline and trastuzumab in breast cancer treatment.
  Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B.
  Oncology (Williston Park) 18 (Suppl 14):59-64, 2004
  
  
• Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
  Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Jänicke F, Thomssen C, Look MP, Foekens JA.
  Clin Breast Cancer 5(5):348-52. Review, 2004
  
  
• Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives.
  Müller V, Pantel K.
  Breast Cancer Res 6: 258-61, 2004
  
  
• Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
  Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ.
  J Natl Cancer Inst. 4;96(15):1141-51, 2004
  
  
• The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas.
  Milde-Langosch K, Röder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Löning T, Bamberger AM.
  Breast Cancer Res Treat 86(2):139-52, 2004
  
  
• The Hamburg statement: the partnership driving the European agenda on breast cancer.
  Jassem J, Buchanan M, Jänicke F, Baum M, Cataliotti L, Kyriakides S, Piccart M, Rutgers EJ, Costa A.
  Eur J Cancer;40(12):1810-1. Review, 2004
  
  
• Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells.
  Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Jänicke F, Sauter G, Pantel K.
  Clin Cancer Res. 10(10):3422-8, 2004
  
  
• High-Dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-Dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
  Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W.
  J Clin Oncol. 22(12):2273-83, 2004
  
  
• HRT - quo vadis.
  Braendle W.
  Frauenarzt 45: 240-242 (2004)
  
  
• Periklimakterium, ab wann hormonelle Therapie?
  Braendle W.
  Gynäkologische Endokrinologie 2: 283-287 (2004) Springer Verlag
  
  
• Konsensusempfehlungen zur Hormontherapie im Klimakterium und in der Postmenopause.
  Beckmann M, Braendle W, Brucker C, Dören M, Emons G., Geisthövel F, Kiesel L, König K, Naß-Griegoleit I, Ortmann O, Rabe Th, Windler E.
  Frauenarzt 45: 620-624 (2004)
  
  
• Empfehlungen zur hormonalen Kontrazeption. 32. Arbeitstreffen Zürcher Gesprächskreis, Mai 2004
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Frauenarzt 45: 1029-1032 (2004)

Publikationen 2003

• Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors.
  Müller V, Pantel K.
  Am J Cancer 2: 77-86, 2003
  
  
• The Million Women Study, an additional observational study with the implications and limits of an observational study.
  Braendle W.
  Maturitas. 46(2):101-2, 2003
  
  
• Detection and characterisation of occult metastatic cells in bone marrow of breast cancer patients.
  Braun S, Müller V, Pantel K.
  Micrometastasis, Kluwer Academic Press, 47-66, 2003
  
  
• Stellungnahme des Zürcher Gesprächskreises zum Gentest [Remarks of the Zürich Discussion Panel on the gene test].
  Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kiesel L.
  Gynäkol Geburtshilfliche Rundsch. 43(1):43-52, 2003
  
  
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
  Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A.
  J Clin Oncol 21(11):2101-9, 2003
  
  
• Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.
  Pantel K, Müller V, Auer M, Nusser N, Harbeck N, Braun S.
  Clin Cancer Res 9: 6326-34, 2003
  
  
• uPA und PAI-1 haben nicht nur eine prognostische, sondern auch eine prädiktive Bedeutung und unterstützen klinische Therapieentscheidungen beim primären Mammakarzinom. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
  Harbeck N, Thomssen C.
  Zentralbl Gynäkol. 125(9):362-7, 2003
  
  
• Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.
  Müller V, Thomssen C, Karakas C, Eustermann I, Ramirez Porras J, Coith C, Berger J, Löning T, Jänicke F, Pantel K.
  Int J Biol Markers 18: 13-20, 2003
  
  
• Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
  Gross E, Ullrich T, Seck K, Müller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M.
  Hum Mutat 22: 498-505, 2003
  
  
• Perspectives in oncology.
  Jänicke F.
  Onkologie26 Suppl 7:3, 2003
  
  
• Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
  Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK, Saeger W.
  Acta Neuropathol (Berl). 106(5):471-8, 2003
  
  
• MR-Mammographie bei 0,5 Tesla: Menstruationszyklusabhängigkeit der Kontrastmittelanreicherung unter hormoneller Kontrazeption? [MR-imaging of the breast at 0.5 Tesla: menstrual-cycle dependency of parenchymal contrast enhancement in healthy volunteers with oral contraceptive use?].
  Lorenzen J, Welger J, Lisboa BW, Krupski G, Adam G.
  RöFo 175(4):502-6, 2003
  
  
• [Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment].
  Schneeweiss A, Thomssen C, Harbeck N, Bastert G.
  MMW Fortschr Med 145(24):34-6, 38, 2003
  
  
• Clinical relevance of prognostic factors in axillary node-negative breast cancer.
  Thomssen C, Jänicke F, Harbeck N.
  Onkologie 26(5):438-45. Review, 2003
  
  
• Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
  Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Jänicke F, Pantel K.
  Int J Cancer. 107(6):903-9, 2003
  
  
• Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
  Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR.
  Cancer Res. 63(19):6523-31, 2003
  
  
• Molecular signature associated with bone marrow micrometastasis in human breast cancer.
  Woelfle U, Cloos J, Sauter G, Riethdorf L, Jänicke F, van Diest P, Brakenhoff R, Pantel K.
  Cancer Res. 63(18):5679-84, 2003
  
  
• Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
  Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens J.
  Thromb Haemost. 90(3):538-48, 2003
  
  
• Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
  Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ.
  Ann Oncol. 14(8):1227-33, 2003
  
  
• Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
  Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Jänicke F, Pantel K.
  Clin Cancer Res. 9(7):2598-604, 2003
  
  
• Konsensus-Empfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause.
  Beckmann MW, Braendle W, Brucker C, Dören M, Emons G, Geisthövel F, Kiesel L, König K, Naß-Griegoleit I, Ortmann O, Rabe T, Windler E.
  Frauenarzt 44: 138-141 (2003)
  
  
• Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 29. Arbeitstreffen des "Zürcher Gesprächskreises", November 2002.
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Frauenarzt 44: 390-394,2003
  
  
• Use of oral contraceptives and risk of cancer of the uterine corpus or ovary. Two case-control studies.
  Heinemann LA, Lewis MA, Kühl-Habich D, Braendle W, Moehner S, Raff T.
  Geburtsh. und Frauenheilkunde 63: 1018-1026 (2003)
  
  
• The Million Women Study, an additional observational study with the implications and limits of an observational study
  Braendle W.
  Maturitas 46: 101-102 (2003)
  
  
• Empfehlungen zur hormonalen Kontrazeption. 30. Arbeitstreffen des Zürcher Gesprächskreises.
  Birkhäuser M, Braendle W, Keller PJ, Kiesel L, Kuhl H, Neulen J.
  Frauenarzt 44, 1270-1273 (2003)
  
  
• Orale Kontrazeption und Brustkrebsrisiko.
  Braendle W.
  Gynäkologe 36: 544-545 (2003)

Publikationen 2002

• Radiotherapy after high-Dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.
  Hoeller U, Heide J, Kröger N, Krüger W, Jänicke F, Alberti W.
  Int J Radiat Oncol Biol Phys. 53(5):1234-9 (2002)
  
  
• Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
  Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.
  Clin Breast Cancer 3(3):196-200. Review, 2002
  
  
• Evidenzbasierte Empfehlungen zur Primärbehandlung von Mammakarzinomen.
  Der Konsens der AGO-Organkommission "Mamma" [Evidence-based recommendations on primary treatment of carcinomas of the breast]
  Von Minckwitz G, Brunnert K, Costa SD, Friedrichs K, Jackisch Ch, Gerber B, Harbeck N, Junkermann H, Mobus V, Nitz U, Schaller G, Scharl A, Thomssen Ch, Untch M; Conssensus of the AGO Organ Commission "Mamma".
  Zentralbl Gynäkol 124(5):293-303. Review, 2002
  
  
• Evidenzbasierte Empfehlungen zur Behandlung von lokoregionär und fernmetastasierten Mammakarzinomen. Der Konsens der AGO-Organkommission "Mamma " [Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]
  Von Minckwitz G, Costa SD, Brunnert K, Dall P, Nitz U, Diel I, Fersis N, Friedrich M, Friedrichs K, Thomssen Ch, Gerber B, Gohring UJ, Harbeck N, Hanf V, Schaller G, Scharl A, Schmutzler R, Simon WE, Untch M; Consensus of the AGO Organ Commission "Mamma".
  Zentralbl Gynäkol 124(5):284-92, 2002
  
  
• Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
  Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.
  J Natl Cancer Inst 94(2):116-28, 2002
  
  
• The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations.
  Schmitt M, Lienert S, Prechtel D, Sedlaczek E, Welk A, Reuning U, Magdolen V, Jänicke F, Sweep CGJ, Harbeck N.
  J Clin Ligand Assay 25: 43-52,2002
  
  
• Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients.
  Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, Habermann CR, Jänicke F.
  Nucl Med Commun 23(9):857-64, 2002
  
  
• Positron emission tomography for the diagnosis of breast cancer.
  Rose C, Dose J, Avril N.
  Nucl Med Commun 23(7):613-8. Review, 2002
  
  
• Endocrinology of climacteric and postmenopause.
  Braendle W.
  Ther Umsch 59(4):199-202, 2002
  
  
• Aktuelle Aspekte in Diagnostik und Therapie des Ovarialkarzinoms.
  Jänicke F.
  GynSpectrum 1: 3 - 6 (Springer Verlag Berlin, Heidelberg)
  
  
• Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
  Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
  Cancer Res 62(16):4617-22, 2002
  
  
• Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
  Friedrichs K, Hoelzel F, Jänicke F.
  Eur J Cancer 38(13):1730-8, 2002
  
  
• Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
  Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study.
  J Clin Oncol. 20(24):4628-35, 2002
  
  
• Perkutane Hochgeschwindigkeitsstanzbiopsie palpabler Brusttumoren: Ist die Sonographie notwendig? [Percutaneous core-needle biopsy of palpable breast tumors. Do we need ultrasound guidance?]
  Lorenzen J, Welger J, Lisboa BW, Riethdorf L, Grzyska B, Adam G.
  RöFo 174(9):1142-6, 2002
  
  
• Expression and localization of the multidrug resistance associated protein 3 in rat small and large intestine.
  Rost D, Mahner S, Sugyama Y, Stremmel W.
  Am Journal of Physiology Gastrointest Liver Physiol 282: G720-G726, 2002
  
  
• Vorstellung der ersten deutschen epidemiologischen Studie zu HRT und Mammakarzinom.
  Braendle W, Berger J, Flesch-Janys D, Hentschel St., Chang-Claude J, Bastert G.
  J. Menopause 2, 29-38 (2002)
  
  
• Postpartale Depression und depressive Zustände im Klimakterium sowie unter der Hormonsubstitution.
  Braendle W, Kuhl H.
  In: Sexualhormone und Psyche (ed. H. Kuhl)Georg - Thieme Verlag, 22-28 (2002)
  
  
• Stellungnahme des Zürcher Gesprächskreises zum Gentest.
  Birkhäuser M, Braendle W, Breckwoldt M, Keller P.J., Kiesel L. Kuhl H.
  Frauenarzt 43, 692-702 (2002)
  
  
• Lifetime history of oral contraceptive use and development of tumours of the uterus and ovary.
  Heinemann, LAJ, Lewis, MA, Kühl-Habich D, Braendle W, Garbe E, Moehner S.
  GebFra 62, 566-573 (2002)
  
  
• The Risk of Breast Tumours and Lifetime History of Oral Contraceptive Use.
  Heinemann LAJ, Lewis, MA, Kühl-Habich D, Braendle W, Moehner S.
  GebFra 62, 750-757 (2002)
  
  
• Stellungnahme zu den Ergebnissen der WHI-Studie.
  Kuhl H. und Braendle W.
  GebFra 62, 917-919 (2002)
  
  
• 28. Arbeitstreffen des Zürcher Gesprächskreises, Mai 2002 , Empfehlungen zur oralen Kontrazeption.
  Birkhäuser M, Braendle W, Breckwoldt M, Keller, PJ, Kiesel L, Kuhl H.
  Frauenarzt 43, Nr. 11, 1318-1322 (2002)

Publikationen 2001

• Disseminated breast cancer cells prior to and after high-dose therapy.
  Krüger WH, Kröger N, Togel F, Renges H, Badbaran A, Hornung R, Jung R, Gutensohn K, Gieseking F, Jänicke F, Zander AR.
  J Hematother Stem Cell Res 10(5):681-9, 2001
  
  
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
  Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
  J Clin Oncol 19(18):3808-16, 2001
  
  
• MAGE-A gene expression pattern in primary breast cancer.
  Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F, Pantel K.
  Cancer Res 61(18):6682-7, 2001
  
  
• Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
  Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M.
  Clin Cancer Res 7(9):2757-64, 2001
  
  
• Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
  Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F.
  Onkologie 24(3):238-44. Review, 2001
  
  
• Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
  Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.
  J Natl Cancer Inst 93(12):913-20, 2001
  
  
• Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
  Krüger W, Kröger N, Togel F, Badbaran A, Renges H, Gieseking F, Gutensohn K, Jänicke F, Zander AR.
  J Hematother Stem Cell Res 10(2):303-7, 2001
  
  
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
  Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M.
  J Clin Oncol 19(10):2596-606, 2001
  
  
• Trials of new combinations of Herceptin in metastatic breast cancer.
  Thomssen C.
  Anticancer Drugs 12 Suppl 4:S19-25. Review, 2001
  
  
• Relationship between telomerase activation and HPV 16/18 oncogene expression in squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix.
  Riethdorf S, Riethdorf L, Schulz G, Ikenberg H, Jänicke F, Löning T, Park TW.
  Int J Gynecol Pathol 20(2):177-85, 2001
  
  
• Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
  Togel F, Datta C, Badbaran A, Kröger N, Renges H, Gieseking F, Jänicke F, Zander AR, Krüger W.
  J Hematother Stem Cell Res 10(1):141-5, 2001
  
  
• Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
  Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M.
  J Nucl Med 42(1):9-16, 2001
  
  
• Regulation der Ovarialfunktion.
  Braendle W.
  In: Endokrinologie und Reproduktionsmedizin I, 4. Auflage (eds. Bender, Diedrich, Künzel). Urban und Fischer. 25-45 (2001)
  
  
• Prävalenz postmenopausaler Hormonsubstitution in Hamburg am Beispiel der Verordnungsdaten der AOK 1998 und TK 1999.
  Flesch-Janys D, Köchel A, Koch P, Berger J, Braendle W.
  GebFra 61: 995-1000 (2001)
  
  
• Empfehlungen zur oralen Kontrazeption. 24. Arbeitstreffen "Zürcher Gesprächskreis" Mai 2000.
  Birkhäuser M, Braendle W, Breckwoldt M, Kuhl H.,Runnebaum B.
  Frauenarzt 41,1053-1058 (2000)
  J. Fertil. Reprod. 1, 36-41 (2001)
  
  
• Ein neues orales Kontrazeptivum mit einem antimineralokortikoid und antiandrogen wirksamen Gestagen (30 µg Ethinylestradiol in Kombination mit 3 mg Drospirenon)
  Braendle W.
  GebFra 61: 101-105 (2001)
  
  
• Estrogene, Gestagene und Brust.
  Braendle W.
  Journal für Menopause 2, 7-11 (2001)
  
  
• Hormonsubstitution und Mammakarzinom. Stellungnahme der Kommission Hormontoxikologie der Deutschen Gesellschaft für Endokrinologie.
  Braendle W.
  Frauenarzt 42, 153 (2001)
  
  
• Sexualhormone und Psyche. Ergebnisse des 2.Interdisziplinären Frankfurter Gesprächs zur Kontrazeption.
  Braendle W, Breckwoldt M, Kuhl H, Riecher-Rössler, Rohde A, Rüther E.
  Frauenarzt 42, 154-160 (2001)
  
  
• Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 25. Arbeitstreffen des"Zürcher Gesprächskreises" November 2000.
  Birkhäuser M, Braendle W, M. Breckwoldt, P.J. Keller, H. Kuhl, B. Runnebaum.
  Frauenarzt 42, 254-258 (2001) und J. Menopause 1, 23-28 (2001)
  
  
• Klinische Pharmakologie.
  Braendle W und Kuhl H.
  Kapitel 18: Sexualhormone und Kontrazeptiva. Rietbrock, Staib und Loew (eds.): Steinkopf Verlag Darmstadt.. 424-438, März 2001
  
  
• Empfehlungen zur oralen Kontrazeption. 26. Arbeitstreffen des "Zürcher Gesprächskreises".
  Birkhäuser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
  Frauenarzt 42: 750-754 (2001)
  
  
• Empfehlungen zur oralen Kontrazeption [Recommendations for oral contraception. 26th Meeting of the "Zürich Discussion Circle" March 2001]
  Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
  Gynäkol Geburtshilfliche Rundsch 41(4):246-9. Review, 2001
  
  
• Östrogensubstitution nach Mammakarzinom? [Estrogen substitution after breast carcinoma?]
  Braendle W.
  Internist (Berl). 42(7):1039, 2001
  
  
• Empfehlungen zur Substitution mit Östrogenen und Gestagenen im Klimakterium und in der Postmenopause [Recommendations for replacement of estrogens and progestins in climacteric and in postmenopause. 25. Arbeitstreffen des "Zurcher Gesprachskreises", November 2000]
  Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
  Gynäkol Geburtshilfliche Rundsch 41(1):12-5, 2001

Publikationen 2000

• Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
  Freue M, Kjaer M, Boni C, Joliver J, Jänicke F, Willemse PH, Coombes RC, Van Belle S, Perez-Carrion R, Zieschang J, Ibarra de Palacios P, Rose C.
  Breast 9(1):9-16, 2000
  
  
• Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
  Jänicke F.
  Clin Breast Cancer 1 Suppl 1:S57-61. Review, 2000
  
  
• Immunomagnetic tumor cell selection--implications for the detection of disseminated cancer cells.
  Krüger W, Datta C, Badbaran A, Togel F, Gutensohn K, Carrero I, Kröger N, Jänicke F, Zander AR.
  Transfusion 40(12):1489-93, 2000
  
  
• Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
  Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M.
  J Clin Oncol 18(8):1689-95, 2000
  
  
• Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
  Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M.
  J Clin Oncol 18(20):3495-502, 2000
  
  
• Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
  Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M.
  Int J Biol Markers 15(1):79-83, 2000
  
  
• Therapy monitoring using FDG-PET in metastatic cervical cancer.
  Dose J, Hemminger GE, Bohuslavizki KH.
  Lancet Oncol 1:106, 2000
  
  
• Das Klimakterium.
  Braendle W.
  Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2000
  
  
• Aktuelle Fragen der Hormonsubstitution.
  Braendle W, Breckwoldt M, Göretzlehner G, Huber J, Keller P.J, Kuhl, H, Metka M, Runnebaum B, Schneider HPG.
  Frauenarzt 41, 176-184 (2000)
  
  
• Unterscheiden sich Gestagene hinsichtlich ihres Risikopotenzials? Gemeinsame Stellungnahme der Deutschen Menopause Gesellschaft, European Menopause and Andropause Society, der Kommission Hormontoxikologie der DGE, der Deutschen Gesellschaft für Senologie, der Deutschen Krebsgesellschaft, der Schweizer Menopause-Gesellschaft und der Österreichischen Menopause-Gesellschaft.
  Braendle W, v. Holst T, Birkhäuser M, Schulz KD, Kreienberg R, Keller PJ, Huber J.
  Frauenarzt 41, 6, 714-718 (2000)
  
  
• Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
  Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F.
  Int J Biol Markers 15(1):73-8, 2000
  
  
• Detection of Intramural Choriocarcinoma of the Uterus with 18F-FDG-PET. A Case Report.
  Dose J, Bohuslavizki K, Hueneke B, Lindner C, Jänicke F.
  Clin Positron Imaging 3(1):37-40, 2000
  
  
• Do we need better prognostic factors in node-negative breast cancer?
  Thomssen C, Jänicke F.
  Eur J Cancer. 36(3):293-8, 2000
  
  
• Sensitivity of assays designed for the detection of disseminated epithelial tumor cells is influenced by cell separation methods.
  Krüger W, Jung R, Kröger N, Gutensohn K, Fiedler W, Neumaier M, Jänicke F, Wagener C, Zander AR.
  Clin Chem 46(3):435-6, 2000
  
  
• The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
  Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
  Cancer Res 60(3):636-43, 2000
  
  
• Anthrazykline beim Mammakarzinom - Zusammenfassung und Perspektiven.
  Jänicke, F.
  Onkologie 23: 26-27, 2000
  
  
• Her-2/neu als prädiktiver Faktor beim Mammakarzinom.
  Konecny G, Pegram M, Untch M, Thomssen C, Jänicke F, Hepp H, Slamon, DJ.
  Geburtsh Frauenheilk 60: 609-619, 2000
  
  
• Decision support in breast cancer: Recent advances in prognostic and predictive techniques.
  Kates R, Harbeck N, Ulm K, Jänicke F, Graeff H, Schmitt M.
  In: Artificial intelligence techniques in breast cancer diagnosis and prognosis: Herausgeber: Jain A. et al. World Scientific Publishing Co.Pte.Ltd., Singapore. S. 55-95, 2000
  
  
• Ovarialkarzinom - Radikale operation als Basis der Primärtherapie.
  Jänicke F.
  Frauenheilk plus (11+12): 491-493, 2000
  
  
• Empfehlungen zur oralen Kontrazeption [Recommendations for oral contraception. 24th meeting of the "Zürich Discussion Circle"]
  Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B.
  Gynäkol Geburtshilfliche Rundsch 40(3-4):172-5, 2000
  
  
• Östrogene, ein Brustkrebsrisiko? [Estrogens--a breast cancer risk?]
  Braendle W.
  Ther Umsch 57(10):646-50, 2000
  
  
• [Postmenopausal hormone replacement under scrutiny. "Fatal therapy"?]
  Braendle W, Semler J.
  MMW Fortschr Med 142(33-34):11-2, 2000

Seitenanfang

Publikationen 1997 bis 2000 (nach Themengebieten)

Brust

Lück, H. J., Thomssen, C., du Bois, A., Lisboa, B., Untch, M., Kühnle, H., Jänicke, F., Meerpohl, H. G., Lindner, C., Konecny, G., Hecker, D., Diergarten, K. (1997): Preliminary results of a phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 24 (Suppl. 3): 13-16.

Avril, N., Bense, S., Ziegler, I., Dose, J., Weber, W., Laubenbacher, C., Römer, W., Jänicke, F., Schwaiger, M. (1997): Breast Imaging with Fluorine-18-FDG PET: Quantitative Image Analysis. J Nucl Med 38: 1186-1191.

Schmitt, M., Thomssen, C., Ulm, K., Seiderer, A., Höfler, H., Jänicke, F., Graeff, H. (1997): Time-varying prognostic impact of tumor biological factors urokinase (uPA) and PAI-1 in breast cancer. Br J Cancer 76: 306-311.

Kuhn, W., Schmalfeldt, B., Pache, L., Prechtl, A., Harbeck, N., Thomssen, C., Jänicke, F., Schmitt, M., Graeff, H. (1997): Stellenwert der tumorassoziierten Proteolyse für Prognose und Therapie des Mamma- und Ovarialkarzinoms. In: IX. Hamburger Symposium über Blutgerinnung. "Blutgerinnung und Blutungskomplikation. Wirkung von Hämostasefaktoren außerhalb des Gerinnungssystems. Basel, Edition Roche (Schattauer Verlag), S. 277-289.

Dose, J., Avril, N., Graeff, H., Jänicke, F. (1997): Positron Emission Tomography for Diagnosis of Breast Tumors. Review Article. Onkologie 20: 190-195.

Harbeck, N., Abdulsalam, A., Jänicke, F. (1997): Clinical relevance of detection of tumor cells in the bone marrow of primary breast cancer patients: A review. Onkologie 20: 387-392.

Avril, N., Dose, J., Ziegler, S., Jänicke, F., Schwaiger, M. (1997): Diagnostik des Mammakarzinoms und der lokoregionären Lymphknoten mit der Positronenemissionstomographie. Radiologe 37: 741-748.

Dose, J., Avril, N., Jänicke, F., Ziegler, S., Bense, S., Römer, W., Weber, W., Graeff, H., Schwaiger, M. (1997): Stellenwert der Positronen-Emissions-Tomographie (PET) mit F-18 Fluordeoxyglukose (FDG) in der Diagnostik von Mammatumoren. Geburtsh Frauenheilk 57: 315-320.

Brauch, H., Löning, T., Jänicke, F. (1997): Normale und neoplastische Morphogenese der Mamma. In: Aktuelle Onkologie 100; W. Braendle, K.D. Schulz (eds.); Zuckschwerdt-Verlag, München, Bern, Wien, New York, pp. 15-27.

Classen, S., Graeff, H., Jänicke, F., Sauer, H., Wilmanns, W. (1997): Prognostische und therapierelevante Faktoren beim Mammakarzinom - Ergebnisse einer Konsensuskonferenz. BUCHHERAUSGABE Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg Excerpta Oncologica. Novartis Pharma Verlag, Nürnberg.

Harbeck, N., Henselmann, B., Thomssen, C., Pache, L., Ulm, K., Dettmar, P., Nathrath, W., Jänicke, F., Schmitt, M., Graeff, H. (1997): Multivariater Vergleich neuerer tumorbiologischer Prognosefaktoren (unter Einschluß von S-Phase und MIB1) beim nodalnegativen Mammakarzinom. In: Excerpta Oncologica. Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg; S. 91-100.

Thomssen, C., Jänicke, F. (1997): Tumorproteasen im multivariaten Vergleich und als Hilfe zur risikoadaptierten Therapieentscheidung. In: Excerpta Oncologica. Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg; S. 135-158.

Graeff, H., Wilmanns, W., Jänicke, F., Sauer, H., Classen, S. (1997): Prognostische und therapierelevante Faktoren beim Mammakarzinom - Ergebnisse einer Konsensuskonferenz. In: Excerpta Oncologica. Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg; S. 11-18.

Knabbe, C., Kopp, A., Müller, V., Brandt, S., Dietz, E., Nollau, P., Zumaier, G. (1997): Endocrine aspects of autocrine and paracrine growth control within the breast. Endocrine-Related Cancer 4: 341-350.

Dettmar, P., Harbeck, N., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., Schmitt, M., Graeff, H., Höfler, H. (1997): Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525-1533.

Hamann, U., Brauch, H., Garvin, A. M., Bastert, G., Scott, R. J. (1997): German family study on hereditary breast and/ovarian cancer: germline mutation analysis of the BRCA1 gene. Genes Chromosomes & Cancer 18:126-132.

Riethdorf, L., Lisboa, B. W., Henkel, U., Naumann, M., Wagener, W. and Löning, T.(1997): Differential Expression of CD66a (BGP), a Cell Adhesion Molecule of the Carcinoembryonic Antigen Family, in Benign, Premalignant, and Malignant Lesions of the Human Mammary Gland. Histochemistry & Cytochemistry, 45:957-963.

Lisboa, B.W., Vogtländer, S., Gilster, T., Riethdorf, L., Milde-Langosch, K. and Löning, T. (1997): Molecular and immuno-histochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Virchows Arch 431:375-381.

Müller, V., Jensen, E. V., Knabbe, C. (1998): Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Research 58 263-267.

Harbeck, N., Dettmar, P., Thomssen, C., Henselmann, B., Kuhn, W., Ulm, K., Jänicke, F., Höfler, H., Graeff, H., Schmitt, M. (1998): Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Research 18:2187-2198.

Harbeck, N., Graeff, H., Höfler, H., Jänicke, F., Schmitt, M. (1998): Klinische Relevanz von Tumorinvasions- und Proliferationsfaktoren beim Mammakarzinom. Geburtsh Frauenheilk 58: 374-381.

Sweep, C. G. J., Geurts-Moespot, J., Grebenschikov, N., de Witte, J. H., Heuvel, J. J. T. M., Schmitt, M., Duffy, M. J., Jänicke, F., Kramer, M. D., Foekens, J. A., Brünner, N., Brugal, G., Pedersen, A., Benraad, T. J. (1998): External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78(11): 1434-1441.

Thomssen, C., Oppelt, P., Jänicke, F., Ulm, K., Harbeck, N., Höfler, H., Kuhn, W., Graeff, H., Schmitt, M. (1998): Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Research 18: 2173-2180.

Avril, N., Dose, J., Jänicke, F., Schwaiger, M. (1998): Positronenemissionstomographie (PET) In: Mammakarzinom - Nuklearmedizinische und radiologische Diagnostik. Hrsg. R. Tilling Springer-Verlag; S.137-157.

Jänicke, F. (1998) Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom. In: Management des Mammakarzinoms. Ein Leitfaden für die Praxis. Hrsg. Kreienberg, Möbus, Alt. Springer Verlag; S.115-132.

Grupp, C., Lindner, Ch., Pfeiffer, G., Jänicke, F. (1998) Reversible paraneoplastische Kleinhirnsymptomatik als Hinweis für ein Mammakarzinom. GebFra 58, 618-619.

Braendle, W.: Hormone und Mammakarzinom. Stellungnahme einer Konsensus-Konferenz. Konsensus-Meeting vom 16.-18.2.1997 in Berlin. In: Hormone und Mammakarzinom (ed. Braendle W. , Schulz K. D.) Zuckschwerdt Verlag (1998).

Friedrichs, K., Jänicke, F. (1999): Neue Wege in der operativen Behandlung des Mammakarzinoms: Kann die Untersuchung des "Sentinel Lymphknotens" die komplette axilläre Lymphonodektomie ersetzen? Hamburger Ärzteblatt 53: 6-9, 2.

Harbeck, N., Thomssen, C., Berger, U., Ulm, K., Höfler, H., Jänicke, F., Graeff, H., Schmitt, M. (1999): Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treatm 1314: 1-11.

Harbeck, N., Dettmar, P., Thomssen, C., Berger, U., Ulm, K., Kates, R., Höfler, H., Jänicke, F., Graeff, H., Schmitt, M. (1999): Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer 80: 419-426, 14, 53.

Stephens, R. W., Brünner, N., Jänicke, F., Schmitt, M. (1999): The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treatm 84: 235-238,12, 79.

Freue, M., Kjaer, M., Boni, C., Jolivet, J., Jänicke, F., Willemse, P. H. B., Coombes, R. C., van Belle, S., Perez-Carrion, R., Zieschang, J., Ibarra de Palacios, P. on behalf of the International AH/BC7 Study Group (1999): Open, randomized comparative trial of formestane versus megesterol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Eur J Cancer 60: 1225-1230, 11, 24.

Bleckmann, C., Dose, J., Bohuslavizki, K., Buchert, R., Klutmann, S., Mester, J., Jänicke, F., Clausen, M. (1999): Effect of attenuation-correction on lesion detectability in F-18 FDG-PET of breast cancer. J Nucl Med 40/12: 2021-2024, 21, 91.

Dose, J., Bohuslavizki, K. H., Bleckmann, C., Clausen, M., Jänicke, F. (1999): Die Positronen-Emissions-Tomographie mit F-18-Fluordeoxyglukose in der Diagnostik des Mammakarzinoms: Möglichkeiten und Perspektiven. Hamburger Ärzteblatt 53: 106-110, 2.

Krüger, W., Tögel, F., Kröger, N., Rössing, S., Gieseking, F., Gutensohn, K., Lindner, Ch., Jänicke, F., Zander, A. R. (1999): Tumor cell detection in G-CSF mobilised stem cells of patients with breast cancer. Medical Oncology 16: 17-22, 15, 07.

Thomssen, C. (1999): Aktuelle Studien zur adjuvanten Therapie des nodalnegativen Mammakarzinoms. In: Mammakarzinom - State of the Art. Medien & Medizin Verlagsges. mbH, München, 2.

Braendle, W.: Hormone und Brustkrebs. Notabene medici, Journal für Ärzte, 7/1999. Notamed Verlag, Melsungen.

Braendle, W.: Regulation der Funktion des Ovars. Klinik der Frauenheilkunde und Geburtshilfe, 1999.

Braun, S., Hepp, F., Sommer, H. L., Kindermann, G., Riethmüller, G., Pantel, K. (1999): Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. Int. J. Cancer 84:1-5, 15, 7.

Braun, S., Hepp, F., Kentenich, C. R. M., Janni, W., Pantel, K., Riethmüller, G., Sommer, H. L. (1999): Monoclonal antibody therapy with Edrecolomab in breast cancer patients: Monitoring the elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin. Cancer Res. 5: 3999-4004, 15, 24.

Friedrichs, K. (1999) Mammakarzinombehandlung bei BRCA-1-positiven Frauen. Chirurg. Praxis 57:489-490, 2.

Chan, S., Friedrichs, K., Noel, D., Pinter, T., van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., Yelle, v. Minckwitz, Korec, S. G., Simmonds, P., Buzzi, F., Gonzalez Mancha, R., Richardson, G., Walpole, E., Ronzoni, M., Murawsky, Alakl, M., Riva, A., Crown, J. (1999): Prospective randomized trial of Docetaxel versus Doxorubicin in patients with metastatic breast cancer. J.Clin. Oncol. 17:2341-2354, 35, 27.

Friedrichs, K., Hölzel, F., Jänicke, F. (1999) Wirkungsweise und Stellenwert der neuen Aromatasehemmer in der Therapie des Mammakarzinoms. Gebh. Frauenheilkunde, 59:245-254, 2.

Jänicke, F. (1999): Therapeutische Konsequenzen beim Mammakarzinom in Abhängigkeit von uPA und PAI-1. Gynäkologische Praxis 23: 453-454, 2.

Avril, N., Menzel, M., Dose, J., Schelling, M., Weber, W., Jänicke, F., Nathrath, W., Schwaiger, M. (2000): Glucose metabolism of breast cancer assessed by FDG-PET: histological and immunohistochemical tissue analysis. J Nucl Med 65: 235-240, 21, 91.

Avril, N., Rose, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S. , Weber, W., Ziegler, S., Graeff, H., Schwaiger, M. (2000): Diagnostic role of breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clinic Oncol 18, 20: 3495-3502, 35, 27.

Schelling, M., Avril, N., Nährig, J., Kuhn, W., Römer, W., Sattler, D., Werner, M., Dose, J., Jänicke, F., Graeff, H., Schwaiger, M. (2000): Positron emission tomography using F-18 fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clinic Oncol Vol 18, No 8: 1689-1695, 35, 27.

Prechtl, A., Harbeck, N., Thomssen, C., Meisner, C., Braun, M., Untch, M., Wieland, M., Lisboa, B., Cufer, T., Graeff, H., Selbmann, K., Schmitt, M., Jänicke, F. (2000): Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int J Biol Markers 15(1): 73-8, 3, 23.

Harbeck, N., Alt, U., Berger, U., Kates, R., Kruger, A., Thomssen, C., Jänicke, F., Graeff, H., Schmitt, M. (2000): Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers. 15: 79-83, 3, 23.

Thomssen, C., Jänicke, F. (2000): Current controversies in cancer: Do we need better prognostic factors in node-negative breast cancer?. pro: Eur J Cancer. 36: 293-8, 11, 24.

Thomssen, C. (2000): Anthrazykline in der adjuvanten Therapie des Mammakarzinoms. Onkologie 23 (suppl 2): 7-11, 2.

Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, CH. R. M., Gastroph, S., Trimpl, A., Wischnik, A., Dimpfl, Th., Kindermann, G., Riethmüller, G., Schlimok, G. (2000): Cytokeratin-positive bone marrow micrometastases and survival of breast cancer patients with stage I-III disease. N. Engl. J. Med. 342: 525-533, 192, 89.

Jänicke, F. (2000): Anthrazykline beim Mammakarzinom - Zusammenfassung und Perspektiven. Onkologie 23: 26-27, 2.

Foekens, J., Peters, H., Look, M., Schmitt, M., Jänicke, F., Klijn, J. et al (2000): The urikinase system of plasminigen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 38, 15.

Thomssen, C. (2000): Nachsorge beim Mammakarzinom. Roche Onkolog. Moderne Therapiestandards beim Mammakarzinom. Roche Onkologie, 2.

Braun, S., Kentenich, C. R. M., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H. L., Pantel, K. (2000): Lack of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18: 80-86, 35, 27.

Cervix und Uterus

Wright Jr., T. C. and Park, Tjoung Won (1997): Cervical Cancer and Its Precursors - An Introduction. Erschienen in: Biology of Female Cancers. p 221-243. CRC Press Boca Raton New York Simon P. Langdon, William R. Miller, Andrew Berchuck eds.

Riethdorf, L., Riethdorf, S., Petersen, S., Bauer, M., Herbst, H., Jänicke, F., Löning, T. (1999): Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol 189: 245-250, 24, 92.

Milde-Langosch, K., Riethdorf, S., Park, T. W. (1999): Natürlicher Verlauf der HPV-Infektion - Nutzen der HPV-Analytik in der Zervix-Diagnostik. Pathologe 20: 15-24, 2, 75.

Riethdorf, S., Park, T. W., Thomssen, C.(1999): Diagnostik und Therapie zervikaler Plattenepithelkarzinome. Pathologe 20: 34-41, 2.

Wright, T. C., Tortolero-Luna, G., Fujiwara, H., Hillemanns, P., Park, T. W., Mitchell, M. F. (1999): HPV Types and p53 mutations in invasive cervical adenocarcinomas: Prevalence and prognostic significance. Cancer.

Wright, T. C., Tortolero-Luna, G., Fujiwara, H., Hillemanns, P., Park, T. W., Mitchell, M. F. (1999): Prognostic significance of Ki-67 antigen (Mib 1) and overexpression of the c-erbB2 protein in invasive cervical adenocarcinoma. Gynecologic Oncology.

Riethdorf, L., Park, T. W., Thomssen, C. (1999): Diagnostik und Therapie zervikaler Plattenepithelkarzinome. Der Pathologe 20; 42 - 49.

Dose, J., Hemminger, G. E., Bohuslavizki, K. H. (2000): Therapy monitoring in metastastic cervical cancer using FDG-PET: clinical picture. The Lancet Oncology Vol 1, Oktober: 106, 2.

Dose, J., Bohuslavisky, S., Jänicke, F. (1999): Detection of intramural choriocarcinoma of the uterus using FDG positron emission tomography: A case report. Positron Imaging 1/3:37-40, 2.

Dose, J., Bohuslavizki, K. H., Hüneke, B., Lindner, Ch., Jänicke, F.: Detection of intramural choriocarcinoma of the uterus with 18-F-FDG-PET: A case report. Clinical Positron Imaging (2000), 3: 37 - 40.

Endometrium

Köhler, U., Hiller, K., Martin, R., Langanke, D., Naumann, G., Bilek, K., Jänicke, F., Schmitt, M. (1997): Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. Gynecol Oncol 66: 268-274.

Löning, T., Reusch, U., Thomssen, C. (1999): Algorithmus der endometrialen Meta- und Hyperplasien Klinik und Pathologie des Endometriumkarzinoms. Der Pathologe 20; 56 - 62, 2, 75.

Löning, T., Reusch,.U., Thomssen, C. (1999): Algorithmus der Klinik und Pathologie des Endometriumkarzinoms. Der Pathologe 20; 63 - 71.

Eierstöcke

Römer, W., Avril, N., Dose, J., Ziegler, S., Kuhn, W., Herz, M., Jänicke, F., Schwaiger, M. (1997): Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose. Fortschr Röntgenstr 166,1: 62-68.

Kuhn, W., Florack, G., Roder, J., Schmalfeldt, B., Pache, L., Rust, M., Ulm, K., Späthe, K., Jänicke, F., Siewert, J. R., Graeff, H. (1998): The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 8: 56-63.

Kuhn, W., Schmalfeldt, B., Pache, L., Späthe, K., Ulm, K., Renziehausen, K., Nöschel, H., Canzler, E., Richter, B., Kröner, M., Tilch, G., Jänicke, F., Graeff, H. (1998): Disease-adapted relapse therapy for ovarian cancer: Results of a prospective study. Int J Oncol 13: 57-63.

Jänicke, F. (1999): Das fortgeschrittene Ovarialkarzinom. Entwicklungen der operativen und systemischen Therapie. Deutsches Ärzteblatt 96 (5): 231-238.

Kuhn, W. , Schmalfeldt, B., Reuning, U., Berger, U., Pache, L., Ulm, K., Höfler, H., Jänicke, F., Schmitt, M., Graeff, H. (1999): Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746-1751, 14, 53.

Dose, J., Jänicke, F. (1999): Ovarialtumoren. In: Kaufmann / Costa (Hrsg.) Facharztbuch Gynäkologie, Springer-Verlag, 95 Seiten, 20.

Park, T. W., Riethdorf, S., Riethdorf, L., Löning, T., Jänicke, F. (1999): Differential telomerase activity, expression of the telomerase catalytic subunit and telomerase-RNA in ovarian tumors. International Journal of Cancer 84: 426-431,15, 7.

Thomssen, C. (2000): Ovarialkarzinom. Sekundäre Eingriffe und Rezidivbehandlung. Frauenheilkunde plus 3: 500-503, 2.

Eileiter

Hüneke, B., Kleinkauf-Houken, A., Lindner, C., Braendle, W.: Überprüfung der Tubendurchgängigkeit mittels gepulster und farbcodierter Duplexdopplersonographie. In: Farbdopplersonographie in Gynäkologie und Geburtshilfe. Herausgegeben von Werner Schmidt und Asim Kurjak. Georg Thieme Verlag, Stuttgart (2000), 73 - 80.

Onkologie allgemein

Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., Graeff, H. (1997): Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thrombosis Hemostasis 78: 285-296.

Brüning, T., Weirich, G., Hornauer, M. A., Höfler, H., Brauch, H. (1997): Renal cell carcinomas in trichloroethene (TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. Archives in Toxicology 71:332-335.

Weirich, G., Schneider, P., Fellbaum, C., Brauch, H., Nathrath, W., Scholz, M., Präuer, H. and Höfler, H. (1997): p53 alterations in thymic epithelial tumors. Virchows Archives 431:17-23.

Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., . Chidambaram, A., Bergerheim, U. F., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J. M., Mc Walther, C. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Störkel, S., Lerman, M. I., Linehan, W. M. and Zbar, B. (1997): Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics 16:68-73.

Weirich, G., Hornauer, M. A., Brüning, T., Höfler, H., Brauch, H. (1997): Fixed archival tissue: purify DNA and primers for good PCR yield. Molecular Biotechnology 8:299-301.

Brauch, H., Hoeppner, W., Jähnig, H., Wöhl, T., Engelhardt, D., Spelsberg, F. and Ritter, M. M. (1997): Sporadic pheochromocytoma are rarely associated with germline mutations in the VHL tumor suppressor gene or the RET proto-oncogene Journal of Clinical Endocrinology and Metabolism 82: 4101-4104.

Bschorer, R., Blake, F., Lisboa, B.W. (1997): Free-flap transfer and the prevention of endothelial damage. Mund Kiefer GesichtsChir 1(4):235-238.

Dose, J., Thomssen, C., Henke, R. P., Habermann, C. R., Braendle, W., Jänicke, F. (1998): Sekundäre Amenorrhoe, subjektive Schwangerschaftszeichen und erhöhte Serum hCG-Werte verursacht durch ein großzelliges Bronchialkarzinom. Geburtsh Frauenheilk 58: 54-57.

Teh, B. T., Blennow, E., Giraud, S., Sahlen, S., Hii, S., Brookwell, R., Brauch, H., Nordenskjöld, M., Larsson, C., Nicol, D. (1998): Bilateral multiple renal oncocytomas and cysts associated with a constitutional translocation (8,9, q24.1, q34.3) and a rare constitutional VHL missense mutation Genes Chromosomes & Cancer 21: 260-264.

Neumann, H. P. H., Bender, B. U., Berger, D. P., Weber, H., Schultze-Seemann, W., Wettereauer, U., Ferstl, F. J., Laubenberger, J., Herbst, E. W., Schwarzkopf, G., Zäuner, I., Hes, F. J., Lips, C. J. M., Lamiell, J. M., Masek, O., Riegler, P., Glavac, D., Brauch, H. (1998): Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. Journal of Urology 160: 1248-1254.

Menschik, T., Lindner, C., Kunert, P., Jänicke, F. (1999): Die schwangerschaftsinduzierte Gigantomastie - ein Krankheitsbild unklarer Genese. Zentralbl Gynäkol 121: 14-17.

Putz, E., Witter, K., Offner, S., Stosiek, P., Zippelius, A., Johnson, J., Zahn, R., Riethmüller, G., Pantel, K. (1999): Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases. Cancer Res. 59: 241-48, 38, 15.

Köllermann, J., Heseding, B., Helpap, B., Köllermann, M. W., Pantel, K. (1999): Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int. J. Cancer 84: 145-149, 15, 7.

Scheunemann, P., Izbicki, J. R., Pantel, K. (1999): Tumorigenic potential of immunocytochemically identifiable tumor cells. N. Engl. J. Med 340: 1687, 192, 89.

Klein, Ch. A., Schmidt-Kittler, O., Schardt, J. A., Pantel, K., P. Speicher, M. R., Riethmüller, G. (1999): Comparative genomic hybridization, loss of heterozygocity and DANN sequence analysis of single cells. Proc. Natl. Acad. Science USA 96: 4494-4499, 2.

Offner, S., Schmaus, W., Wiiter, K., Baretton, G. B., Schlimok, G., Passlick, B., Riethmüller, G., Pantel, K. (1999): p53 gene mutations are not required for early dissemination of cancer cells. Proc. Natl. Acad. Science USA 96: 6942-6946, 2.

Pantel, K., Wittner, K. (1999): Detection of disseminated epithelial tumor cells: Methods an clinical implications. Infusion Therapy and Transfusion Medicine 26: 10-14,7, 78.

Pantel, K. and Otte, M. (1999): Identification of therapeutic targets on micrometastases. Hematol. Cell Ther.

Pantel, K., Cote, R. and Fodstad, O. (1999): Detection and clinical significance of micrometastatic desease. J. Natl. Cancer Inst.

Pantel, K. und Riethmüller, G. (1999): Micrometastases in bone marrow. In: Albert, W., Baak, J. P., Karin, D.(eds.), Laboratorytesting of solid tumors, Blackwell Scientific.

Kneba, M., Keilholz, U., Lion, T. Pantel, K., Zoubek, A. (1999): Klinische Bedeutung des Nachweises der minimalen Residualerkrankung bei Leukämien, Lymphomen und soliden Tumoren. In: H. J. Schmoll, K. Höffken, K. Possinger (eds.) Kompendium Internistische Onkologie, 3. Auflage, Springer Verlag Berlin.

Dose, J., S. Bohuslavisky, F. Jänicke (1999): Detection of intramural choriocarcinoma of the uterus using FDG positron emission tomography: A case report. J Nuc Med.

Thomssen, C., Harbeck, N., Schmitt, M., Graeff, H., Jänicke, F. (1999): Bestimmung der Konzentration von Proteolysefaktoren in Gewebe und Plasma: Nutzen der Methode zur Beurteilung von Prognose und Verlauf. In: R. Matthias, H. Rasche (Hrsg.), Onkologie und Hämostasesystem. 41. Hamburger Symposion über Blutgerinnung am 12. Und 13. Juni 1998. Stuttgart, Schattauer, 2.

Thomssen, C., Jänicke, F. (1999) Gynäkologische Tumoren. In: Wilmann, H. et al (Hrsg.) Therapie Handbuch. Urban & Schwarzenberg München, Wien, Baltimore, 2.

Roder, J. D., Thorban, S., Pantel, K., Siewert, J. R. (1999): Micrometastases in bone marrow: Prognostic indicators for pancreatic cancer. World J. Surg. 23:888-91, 18,18.

Passlick, B., Kubuschok, B., Izbicki, J. R., Thetter, O., Pantel, K. (1999): Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann. Thor. Surg. 68: 2053-2058, 2.

Borgen, E., Naume, B., Nesland, J. M., Kvalheim, G., Beiske, K., Fodstad, Diel, I., Solomayer, E.-F., Theocharous, P., Coombes, R. C., Smith, B. M., Wunder, E., Marolleau, J.-P., Garcia, J., and Pantel, K. (1999): Standardization of the immunocytochemical detection of cancer cells in BM and blood: l. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1: 377-388, 2.

Ahr, A., Scharl, A., Muller, M., von Minckwitz, G., Gatje, R., Pantel, K., Kaufmann, M. (1999): Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11. Int. J. Cancer. 84: 502-5, 15, 7.

Pantel, K. (1999): Residuelle Tumorzellen: Diangostische Ansätze, prognostische Relevanz, Biologie und Antikörpertherapie. Tumordiagn. U. Ther. 20: 131-34, 2.

Pantel, K., Cote, R., Fodstad, O. (1999): Detection and clinical relevance of micrometastatic disease. J. Natl. Cancer Inst. 91: 1113-24, 57, 33.

Braun, S. and Pantel, K. (1999): Micrometastatic bone marrow involvement: detection and prognostic significance. Medical Oncology 16: 154-165, 4, 18.

Riethmüller, G., Klein, Ch., Pantel, K. (1999): Hunting down the seminal cells of clinical metastases. Immunol. Today 20:294-296, 72, 91.

Pantel, K. (1999): Minimal residual disease. Introductory overview. Cancer Metastasis Rev. 18: 1-2, 7, 1.

Braun, S. and Pantel, K. (1999): Biological characteristics of micrometastatic cancer cells in bone marrow. Cancer and Metastasis Reviews. 18: 75-90, 7, 1.

Thomssen, C., Jänicke, F. (1999): Bestimmung der Konzentration von Proteolysefaktoren in Gewebe und Plasma: Nutzen der Methode zur Beurteilung von Prognose und Verlauf. In: Onkologie und Hämostasesystem. 41. Hamburger Symposium über Blutgerinnung. Matthias, F. R., Rasche, H. (Hrsg.), Ed. Roche, Schattauer; Stuttgart, Basel, Grenzach-Wyhlen, 109 -129, 5.

Zippelius, A., Lutterbüse, R., Riethmüller, G., Pantel, K. (2000): Analytical variables of reverse transcrition-polymerase chain reaction-based detection of disseminated prostate cancer cells. Clin. Cancer Res. 6: 2741-50, 15, 24.

Passlick, B., Sienel, W., Seen-Hibler, R., Wöckel, W., Thetter, O., Pantel, K. (2000): The 17-1A antigen is expressed on primary. Metastatic, and disseminated non-small cell lung carcinoma cells. Int. J. Cancer 87: 548-552, 15, 7.

Gehling, U., Ergün, S., Schumacher, U., Wagener, Ch., Pantel, K., Otte, M., Schuch, G., Schafhausen, Ph., Mende, Th., Kilic, N., Kluge, K., Schäfer, B., Hossfeld, D. K., Fiedler, W. (2000): In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95: 3106-12 41, 31.

Passlick, B., Sienel, W., Seen-Hibler, R., Wöckel, W., Thetter, O., Mutschler, W., Pantel, K. (2000): Overexpression of Matrix Metalloproteinase 2 predicts unfavorable outcome in early stage non-small cell lung cancer. Clin. Cancer Res. 6: 3944-48 15, 24.

Hosch, S., Kraus, J., Scheunemann, P., Izbicki, J. R., Schneider, C., Schumacher, U., Witter, K., Speicher, M., Pantel, K. (2000): Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res., 60: 6836-40, 38, 15.

Pantel, K. and von Knebel Doeberitz, M. (2000): Detection and clinical relevance of micrometastatic cancer cells. Curr. Opin. Oncol. 12: 95-101, 2.

Zippelius, A. and Pantel, K.: RT-PCR based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. Ann NY Acad. Sci. 906: 110-123, 2.

Passlick, B., Pantel, K. (2000): Detection and relevance of immunohistochemically identifiable tumor cells in lymph nodes. Recent Results in Cancer Res. 157:29-37, 2.

Pantel, K., Otte, M. (2000) : Disseminated tumor cells: Diagnosis, prognostic relevance, and phenotyping. Recent Results in Cancer Res. 158: 14-24, 2.

Braun, S., Pantel, K. (2000): Diagnostik und klinische Bedeutung von disseminierten Tumorzellen im Knochenmark. Dtsch. Med. Wschr. 125:1237-39, 2.

Izbicki, J. R., Hosch, S., Hossfeld, D. K., Pantel, K. (2000): Minimale residuale Tumorerkrankung bei soliden epithelialen Tumoren. Dt. Ärzteblatt 22:1526-32, 2.

Pantel, K., Otte, M. (2000) : Identification and characterization of minimal residual disease in solid tumors. Acta Medica Austriaca 27: 8-12, 2.

Thomssen, C., Löning, T. (2000): Sarkome der weiblichen Genitalorgane. In: Klinik der Frauenheilkunde und Geburtshilfe, Band 11: Spezielle gynäkologische Onkologie I, Bender HG (Hrsg.); 4. Auflage. Urban und Fischer Verlag, München, 2.

Geburtshilfe

Schröder, H. J., Power, G. G.: Engine and radiator: fetal and placental interactions for heat dissipation. Exper Physiol, 82, 403 (1997).

Kertschanska, S., Schröder, Kaufmann, H., P.: The ultrastructure of the trophoblastic layer of the degu (Octodon degus) Placenta: a re-evaluation of the "channel problem". Placenta 18, 218 (1997).

Braendle, W.: Schwangerschaftsverlauf ohne zusätzliches Risiko nach in vitro Fertilisation. In: Prägravide Risiken (Dudenhausen, J.W.). Früherkennung und Beratung vor der Schwangerschaft. Umwelt und Medizin, Verlagsgesellschaft Frankfurt/Mainz 1997.

Kleinkauf-Houcken, A., Hüneke, B., Lindner, Ch. and Braendle, W.: Combining B-mode ultrasound with pulsed wave Doppler for the assessment of tubal patency. Human Reproduction vol 12, no. 11, 2457- 2460, 1997.

Tchirikov, M., Schröder, H. J.: Single case report: late gestational sheep may survive blockage of the ductus venosus for 1 week. Placenta 19, 333 (1998).

Tchirikov, M., Rybakowski, Ch., Hüneke, B., Schröder, H. J.: Blood flow through the ductus venosus in singleton and multifetal pregnancies and in fetuses with intrauterine growth retardation. Am J Obstet Gynecol, 178, 943 (1998).

Tchirikov, M., Eisermann, K., Rybakowski, C., Schröder, H. J.: Doppler ultrasound evaluation of ductus venosus blood flow during acute hypoxemia in fetal lambs. Ultrasound Obstet Gynecol, 11: 426 (1998).

Schröder, H. J., Dehne, K., Andreas, Th., Rägo, S., Rybakowski, Ch.: Diffusive transfer of water and glucose across the chorionic plate of the isolated human term placenta. Placenta 20, 59 (1999).

Tchirikov, M., Hüneke, B., Schröder, H. J.: Ductus venosus als Regulator des fetalen Wachstums? Arch Gynec Obstet, 263 (suppl 2), 109 (1999).

Kleinkauf-Houcken, A., Hüneke, B., Lindner, Ch., Braendle, W.: Combining B-rnode ultrasound with pulsed wave Doppler for the assessment of tubal patency. Human Reproduction (1997), 12: 2457 - 2460.

Tchirikov, M., Rybakowski, Ch., Hüneke, B., Schröder, H. J.: Blood flow through the ductus venosus in singleton and multifetal pregnancies and in fetuses with intrauterine growth retardation. Am J Obstet Gynecol (1998), 178: 943 - 949.

Henschen, S., Cetin, E., Hüneke, B.: Das BELLP-Syndrom. Eine bedrohliche Erkrankung in der Schwangerschaft. Hamburger Ärzteblatt (1998), 52: 294 - 297.

Dose, J., Thomssen, C., Henke, R. P., Habermann, C. R., Braendle, W., Jänicke, F.: Sekundäre Amenorrhoe, subjektive Schwangerschaftszeichen und erhöhte Serum-hCG-Werte verursacht durch ein großzelliges Bronchialkarzinom. Geburtsh. u. Frauenheilk. 58, 54-57 (1998).

Hoof, K., Hüneke, B., Gassner, C., Brauch, H.: PCR-based RH-genotyp'mg with fetal DNA isolated using Q1Aamp technology. QIAGENews (1999), 4: 19 - 20.

Standt, Th., Wilhex, S., Gnirke, A., Hüneke, B.: Aktuelle Entwicklungen der geburtshilflichen Regionalanästhesie - Eine Übersicht am Beispiel des Universitäts-Krankenhauses Eppendorf. Anästhesiol.Intensivmed.Notfallmed.Schmerzther. (1999), 34: 648 - 658.

Rybakowski, C., Eisermann, K., Tchirikov, M., Schöder, H. (2000): Efficacy of carotid collateral perfusion in anaesthetised sheep fetuses. Placenta 21: 718-715, 12, 49.

Schöder, H., Rybakowski, C., Eisermann, K., Ostermann, S. (2000): Unloading of baroreceptors by carotid occlusion does not increase heart rate in fetal sheep. European J of Obstetrics and Gynäcology and Perinatal Biology 92: 265-272, 5, 89.

Rybakowski, C., Niemax, K., Goepel, E., Schröder, H. (2000): The Effect of Oxytocin, Prostaglandine E2 and Acetylsalicylic Acid on Flow Distribution and on the Transfer of Alanine, Glucose and Water in Isolated Perfused Guine Pig Placenta. Placenta 21: 126-131, 12, 49.

Hüneke, B.: Pränatale Diagnostik und perinatales Management bei kongenitalen Harntraktfehlbildungen. Gyn Praktische Gynäkologie (2000), 5: 88 - 95.

Zhou, X. B., Wang, G. X., Hüneke, B., Wieland, T., Korth, M.: Pregnancy switches adrenergic signal transduction in rat and human uterine myocytes as probed by BKCa channel activity. J. Physiol (2000), 524.2: 339 - 352.

Hüneke, B., Entwicklung der Frühgeburtlichkeitsrate sowie der Rate vaginal- und abdominal-operativer Entbindungen in Hamburg (1982 - 1998). Hamburger Ärzteblatt (2000), 8: 304 - 308.

Hüneke, B., Pränatale Diagnostik und Therapie bei intrauteriner Wachstumsrestriktion. Gyn Praktische Gynäkologie (2000), 5: 246 - 255.

Zhou, X. B., Wang, G. X., Ruth, P., Hüneke, B., Korth, M.: BK (Ca) channel activation by membrane-associated cGMP kinase may contribute to uterine quiescence in pregnancy. Am J Physiol Cell Physiol (2000), Dec, 279 (6): C 1751 - 9.

Hormonale Kontrazeption

Braendle, W.: Norethisteron in der hormonalen Kontrazeption - ein historischer Überblick. In: Norethisteron zur oralen Kontrazeption und Substitution (eds. T. von Holst, G. Schramm) Berichtsband vom NET-Experten-Workshop Salzburg, 31.1. bis 2.2.1997, Schattauer Verlag 1997.

Runnebaum, B., Bettendor,f G., Breckwoldt, M., Keller, P., Kuhl, H. und Braendle, W.: 18. Arbeitstreffen des "Zürcher Gesprächskreises" April 1997. Empfehlungen zur oralen Kontrazeption. Der Frauenarzt 38. Jahrgang, 7/1997.

Braendle, W., A. Kleinkauf-Houcken: Hormonale Kontrazeption - Aktueller Stand und Neuentwicklungen. Gynäkologe, Heft 5, 417-425 (1998).

Birkhäuser, M., Breckwoldt, M., Kelle, P. J., Kuhl, H., Runnebaum, B., Braendle, W.: Empfehlungen zur oralen Kontrazeption. 22. Arbeitstreffen des "Zürcher Gesprächskreises" 1999 Frauenarzt 7, 925-928 (1999).

Klimakterium

Braendle, W.: Anwendung klinischer Erfahrungen bei z. Zt. noch nicht zugelassenen Indikationen. Internationaler Menopause-Kongreß Sydney 4. Bis 7.11.1996. Menopause-Praxis 2, 1-3, Georg Thieme Verlag, Stuttgart - New York , Oktober 1997.

Bettendorf, G., Braendle, W., Breckwoldt, M., Keller, P. J., Kuhl, H. und Runnebaum, B.: Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 17. Arbeitstreffen des Zürcher Gesprächskreises. Geburtsh. und Frauenheilk. 57, 178 - 181, Georg-Thieme Verlag , 1997.

Braendle, W: Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 19. Arbeitstreffen des "Zürcher Gesprächskreises", Dezember 1997 Frauenarzt, 3, 358-362, 1998.

Kleinkauf-Houcken, A., Braendle, W.: Möglichkeiten der hormonellen Substitutionstherapie im Klimakterium. Der Gynäkologe 31, 848-858 (1998).

Birkhäuser, M., Breckwoldt, M., Keller, P. J., Kuhl, H., Runnebaum, B., Braendle, W.: Empfehlungen zur Substitution mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. 21. Arbeitstreffen Zürcher Gesprächskreis, November 1998. Frauenarzt 2/1999, 153-155.

Braendle, W.: Das Klimakterium. Wissenschaftliche Verlagsgesellschaft, Stuttgart, Dezember 1999.

Braendle, W., Birkhäuser, M., Felsenberg, D., Göretzlehner, G., Heinemann, L., von Holst, T., Huber, J. and Kuhl, H.: Stellenwert von Norethisteronacetat in der modernen Hormonsubstitution. Expertenmeeting vom 13.-14.5.99, Bergisch Gladbach. Frauenarzt 7/1999.

Henschen, S., Gronewold, M., Thomssen, C., Riethdorf, L., Jänicke, F. (1999): Kasuistik einer Leiomyomatose pelviner Lymphknoten unter Östrogensubstitution. Geburtsh Frauenheilk 59: 37-40, 2.